Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein

Anesthesiology

Volumn 96, Issue 4, 2002, Pages 913-920

  Wandel, Christoph ^a,b,c   Kim, Richard ^a   Wood, Margaret ^d,e   Wood, Alastair ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BAYER AG   (Germany)

^d College of Physicians and Surgeons ^*  (United States)

^e Department of Anesthesiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; DIGOXIN; FENTANYL; GLYCOPROTEIN P; LOPERAMIDE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; SUFENTANIL; TRITIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MEMBRANE BINDING; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALFENTANIL; ANALGESICS, OPIOID; ANIMALS; ANTIDIARRHEALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; HUMANS; LOPERAMIDE; MORPHINE; P-GLYCOPROTEIN; SUFENTANIL;

EID: 0036206856     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200204000-00019     Document Type: Article

References (33)

1. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
2. Immunohistocheinical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with muscle protein
3. Genetic dissection of function of mammalian P-glycoproteins
4. Genetic analysis of the multidrug transporter
5. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblstine by verapmail
6. Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations
7. Clinical trials of agents that reverse multidrug resistance
8. Pharmacology of drugs that alter multidrug resistance in cancer
9. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
10. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
11. Substantial excretion of digoxin via the intestinal-mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
12. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
13. Drug distribution: Less passive, more active?
14. Effects of cyclosporin on anesthetic action
15. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein
16. Functional polymorphisms of the human multiresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
17. Increased drug delivery to the brain by P-glycoprotein inhibition
18. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine A
19. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
20. P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies
21. Ethnic differences in response to morphine
22. Active transport of fentanyl by the blood-brain barrier
23. Inhibition of p-glycoprotein converts loperamide from an inactive to a centrally active opioid
24. Effect of GF120918, a potent p-glycoprotein inhibitor, on morphine pharmacokinetics pharmacodynamics in the rat
25. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine
26. Function of P-glycoprotein expressed in placenta and mole
27. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice
28. In vitro and in vivo drug interactions involving human CYP 3A
29. Effect of cardiopulmonary bypass on fentanyl distribution and elimination
30. Fentanyl infusion anesthesia for aortocoronary bypass surgery: Plasma levels and hemodynamic response
31. Sufentanil disposition during cardiopulmonary bypass
32. The effect of cardiopulmonary bypass on plasma protein binding of alfentanil
33. Fatal fentanyl intoxication following excessive transdermal application